Monday, September 13, 2021 12:15:20 PM
Placebo stuff again?
Aw, that's just awful news.
Everyone knows that if patients in a clinical trial of a drug actually don't know if the pill they are taking is real, by the placebo effect they will mentally work up and produce otherwise invalid clinical results.
So, in the Open Label Extension (OLE) study, any good results will just have to be attributed to the placebo effect, not blarcamesine itself.
I know of the placebo effect, in Alzheimer's myself. My father, an accomplished public accountant, began to have trouble remembering things. My mother, an experienced geriatric nurse, saw things exactly. Dad had Alzheimer's setting in.
Because of her medical contacts, mother enrolled dad in one of the FDA-approved clinical studies of Aricept (donepezil) at a nearby medical school. Not long into the study, mother said that whatever this new drug was, if dad was in the experimental (drug-taking) arm of the study, it was producing no therapeutic results. Dad's cognition continued to decline unabated through the entire long trial period.
For me, in this particular incident, it proved one of two things: a) if my dad was taking donepezil, it failed; or b) if he wasn't, was in the control arm of the study, taking a disguised starch pill, he was unable to generate any sort of placebo effect. By the force of mental willpower ("I'm taking a powerful new drug that will help!"), he was unable to reverse any Alzheimer's symptom. There can be no placebo effect in Alzheimer's. Determined or hoped-for willpower can't fix the biochemical anomalies of the neurons in Alzheimer's.
So, let's watch; to see how the OLE results are interpreted by the news media. Will they be attributed to blarcamesine itself, or to the placebo effect?
NO BLINDING OF THE Open Label Extension Study
Aw, that's just awful news.
Everyone knows that if patients in a clinical trial of a drug actually don't know if the pill they are taking is real, by the placebo effect they will mentally work up and produce otherwise invalid clinical results.
So, in the Open Label Extension (OLE) study, any good results will just have to be attributed to the placebo effect, not blarcamesine itself.
I know of the placebo effect, in Alzheimer's myself. My father, an accomplished public accountant, began to have trouble remembering things. My mother, an experienced geriatric nurse, saw things exactly. Dad had Alzheimer's setting in.
Because of her medical contacts, mother enrolled dad in one of the FDA-approved clinical studies of Aricept (donepezil) at a nearby medical school. Not long into the study, mother said that whatever this new drug was, if dad was in the experimental (drug-taking) arm of the study, it was producing no therapeutic results. Dad's cognition continued to decline unabated through the entire long trial period.
For me, in this particular incident, it proved one of two things: a) if my dad was taking donepezil, it failed; or b) if he wasn't, was in the control arm of the study, taking a disguised starch pill, he was unable to generate any sort of placebo effect. By the force of mental willpower ("I'm taking a powerful new drug that will help!"), he was unable to reverse any Alzheimer's symptom. There can be no placebo effect in Alzheimer's. Determined or hoped-for willpower can't fix the biochemical anomalies of the neurons in Alzheimer's.
So, let's watch; to see how the OLE results are interpreted by the news media. Will they be attributed to blarcamesine itself, or to the placebo effect?
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
